Tokyo, March 6 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060821) titled 'A medical chart review evaluating pregnancy outcomes and infant safety in pregnant patients with neuromyelitis optica spectrum disorder (NMOSD) who were exposed to satralizumab' on March 6.
Study Type:
Observational
Primary Sponsor:
Institute - Chugai Pharmaceutical Co., Ltd.
Condition:
Condition - Neuromyelitis optica spectrum disorder
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate the impact of satralizumab on pregnancy outcomes in patients with neuromyelitis optica spectrum disorder (NMOSD)
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lowe...